Skip to main content
NCBI home page
Antimicrobial Agents and Chemotherapy logoLink to Antimicrobial Agents and Chemotherapy
. 1984 Jan;25(1):33–36. doi: 10.1128/aac.25.1.33

Pharmacokinetics of moxalactam in elderly subjects.

M H Andritz, R P Smith, A L Baltch, P E Griffin, J V Conroy, N Sutphen, M C Hammer
PMCID: PMC185429  PMID: 6703682

Abstract

The pharmacokinetics of moxalactam were studied in 19 male volunteers 60 years of age or older with normal liver function tests and a creatinine clearance of greater than or equal to 60 ml/min. Moxalactam was administered in single or multiple intravenous or intramuscular doses. Rapid and complete intramuscular bioavailability was demonstrated in a subgroup of the study population. The mean plasma half-life was 2.9 +/- 0.8 h for intravenous doses and 3.5 +/- 0.9 h for intramuscular doses. Average renal clearances of 0.04 liters/kg per h accounted for 74.0 +/- 15.0% of total plasma clearance. Moxalactam plasma clearance showed a statistically significant (P less than 0.01) correlation with measured and calculated creatinine clearance. The major differences in moxalactam pharmacokinetics seen in the elderly appear to be related to diminishing renal function and highly variable nonrenal elimination. Creatinine clearance can be used in estimating moxalactam doses in the elderly without significant renal impairment, but recommendations for the use of serum creatinine as an estimation of renal function or drug half-life are not valid in this population group.

Full text

PDF
33

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Aronoff G. R., Sloan R. S., Luft F. C. Pharmacokinetics of moxalactam in patients with normal and impaired renal function. J Infect Dis. 1982 Mar;145(3):365–369. doi: 10.1093/infdis/145.3.365. [DOI] [PubMed] [Google Scholar]
  2. Aronoff G. R., Sloan R. S., Mong S. A., Luft F. C., Kleit S. A. Moxalactam pharmacokinetics during hemodialysis. Antimicrob Agents Chemother. 1981 Apr;19(4):575–577. doi: 10.1128/aac.19.4.575. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Bolton W. K., Scheld W. M., Spyker D. A., Overby T. L., Sande M. A. Pharmacokinetics of moxalactam in subjects with various degrees of renal dysfunction. Antimicrob Agents Chemother. 1980 Dec;18(6):933–938. doi: 10.1128/aac.18.6.933. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Crooks J., O'Malley K., Stevenson I. H. Pharmacokinetics in the elderly. Clin Pharmacokinet. 1976;1(4):280–296. doi: 10.2165/00003088-197601040-00003. [DOI] [PubMed] [Google Scholar]
  5. DeSante K. A., Israel K. S., Brier G. L., Wolny J. D., Hatcher B. L. Effect of probenecid on the pharmacokinetics of moxalactam. Antimicrob Agents Chemother. 1982 Jan;21(1):58–61. doi: 10.1128/aac.21.1.58. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Foster T. S., Bourne D. W. Use of a programmable hand-held calculator for clinical pharmacokinetics. Am J Hosp Pharm. 1977 Jan;34(1):70–75. [PubMed] [Google Scholar]
  7. Garzone P., Lyon J., Yu V. L., Zuravleff J., Diven W., Pasculle W. Steady-state moxalactam kinetics: comparisons with other cephalosporins. Clin Pharmacol Ther. 1981 Jul;30(1):86–94. doi: 10.1038/clpt.1981.131. [DOI] [PubMed] [Google Scholar]
  8. Greenblatt D. J., Sellers E. M., Shader R. I. Drug therapy: drug disposition in old age. N Engl J Med. 1982 May 6;306(18):1081–1088. doi: 10.1056/NEJM198205063061804. [DOI] [PubMed] [Google Scholar]
  9. Israel K. S., Black H. R., Brier G. L., Wolny J. D., DeSante K. A. Single- and multiple-dose pharmacokinetics of moxalactam in normal subjects. Antimicrob Agents Chemother. 1982 Jul;22(1):94–102. doi: 10.1128/aac.22.1.94. [DOI] [PMC free article] [PubMed] [Google Scholar]
  10. Jacobson E. J., Zahrowski J. J., Nissenson A. R. Moxalactam kinetics in hemodialysis. Clin Pharmacol Ther. 1981 Oct;30(4):487–490. doi: 10.1038/clpt.1981.192. [DOI] [PubMed] [Google Scholar]
  11. Lam M., Manion C. V., Czerwinski A. W. Pharmacokinetics of moxalactam in patients with renal insufficiency. Antimicrob Agents Chemother. 1981 Mar;19(3):461–464. doi: 10.1128/aac.19.3.461. [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. Leroy A., Humbert G., Fillastre J. P. Pharmacokinetics of moxalactam in subjects with normal and impaired renal function. Antimicrob Agents Chemother. 1981 Jun;19(6):965–971. doi: 10.1128/aac.19.6.965. [DOI] [PMC free article] [PubMed] [Google Scholar]
  13. Lüthy R., Blaser J., Bonetti A., Simmen H., Wise R., Siegenthaler W. Comparative multiple-dose pharmacokinetics of cefotaxime, moxalactam, and ceftazidime. Antimicrob Agents Chemother. 1981 Nov;20(5):567–575. doi: 10.1128/aac.20.5.567. [DOI] [PMC free article] [PubMed] [Google Scholar]
  14. Martinez O. V., Levi J. U., Livingstone A., Malinin T. I., Zeppa R., Hutson D., Einhorn N. Biliary excretion of moxalactam. Antimicrob Agents Chemother. 1981 Aug;20(2):231–234. doi: 10.1128/aac.20.2.231. [DOI] [PMC free article] [PubMed] [Google Scholar]
  15. Mawer G. E., Lucas S. B., Knowles B. R., Stirland R. M. Computer-assisted prescribing of kanamycin for patients with renal insufficiency. Lancet. 1972 Jan 1;1(7740):12–15. doi: 10.1016/s0140-6736(72)90005-0. [DOI] [PubMed] [Google Scholar]
  16. Perrier D., Mayersohn M. Noncompartmental determination of the steady-state volume of distribution for any mode of administration. J Pharm Sci. 1982 Mar;71(3):372–373. doi: 10.1002/jps.2600710332. [DOI] [PubMed] [Google Scholar]
  17. Polk R. E., Kline B. J., Markowitz S. M. Cefazolin and moxalactam pharmacokinetics after simultaneous intravenous infusion. Antimicrob Agents Chemother. 1981 Nov;20(5):576–579. doi: 10.1128/aac.20.5.576. [DOI] [PMC free article] [PubMed] [Google Scholar]
  18. Romagnoli M. F., Flynn K., Siber G. R., Goldmann D. A. Moxalactam pharmacokinetics in children. Antimicrob Agents Chemother. 1982 Jul;22(1):47–50. doi: 10.1128/aac.22.1.47. [DOI] [PMC free article] [PubMed] [Google Scholar]
  19. Scheld W. M., Spyker D. A., Donowitz G. R., Bolton W. K., Sande M. A. Moxalactam and cefazolin: comparative pharmacokinetics in normal subjects. Antimicrob Agents Chemother. 1981 Apr;19(4):613–619. doi: 10.1128/aac.19.4.613. [DOI] [PMC free article] [PubMed] [Google Scholar]
  20. Sedman A. J., Wagner J. G. CSTRIP, a fortran IV computer program for obtaining initial polyexponential parameter estimates. J Pharm Sci. 1976 Jul;65(7):1006–1010. doi: 10.1002/jps.2600650713. [DOI] [PubMed] [Google Scholar]
  21. Siersbaek-Nielsen K., Hansen J. M., Kampmann J., Kristensen M. Rapid evaluation of creatinine clearance. Lancet. 1971 May 29;1(7709):1133–1134. doi: 10.1016/s0140-6736(71)91873-3. [DOI] [PubMed] [Google Scholar]
  22. Srinivasan S., Fu K. P., Neu H. C. Pharmacokinetics of moxalactam and cefazolin compared in normal volunteers. Antimicrob Agents Chemother. 1981 Feb;19(2):302–305. doi: 10.1128/aac.19.2.302. [DOI] [PMC free article] [PubMed] [Google Scholar]
  23. Srinivasan S., Neu H. C. Pharmacokinetics of moxalactam in patients with renal failure and during hemodialysis. Antimicrob Agents Chemother. 1981 Sep;20(3):398–400. doi: 10.1128/aac.20.3.398. [DOI] [PMC free article] [PubMed] [Google Scholar]
  24. Wagner J. G. Linear pharmacokinetic equations allowing direct calculation of many needed pharmacokinetic parameters from the coefficients and exponents of polyexponential equations which have been fitted to the data. J Pharmacokinet Biopharm. 1976 Oct;4(5):443–467. doi: 10.1007/BF01062831. [DOI] [PubMed] [Google Scholar]

Articles from Antimicrobial Agents and Chemotherapy are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES